Patents by Inventor Daniel Tyler Richter
Daniel Tyler Richter has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10676471Abstract: The present invention relates to compounds of formula (I) or pharmaceutically acceptable salts thereof, wherein A, L, D, R1-R15, w, x, y, and z are defined herein. The novel cycloalkyl-linked diheterocycle derivatives that are useful in the treatment of abnormal cell growth, such as cancer, in mammals. The present invention also relates to pharmaceutical compositions containing the compounds and to methods of using the compounds and compositions in the treatment of abnormal cell growth in mammals.Type: GrantFiled: May 20, 2019Date of Patent: June 9, 2020Assignee: Pfizer Inc.Inventors: Aaron Craig Burns, Michael Raymond Collins, Samantha Elizabeth Greasley, Robert Louis Hoffman, Peter Qinhua Huang, Robert Steven Kania, Pei-Pei Kung, Maria Angelica Linton, Lakshmi Sourirajan Narasimhan, Paul Francis Richardson, Daniel Tyler Richter, Graham Smith
-
Patent number: 10570121Abstract: This invention relates to compounds of general formula (I) in which R1, R2, R3, R4, L, X and Z are as defined herein, and the pharmaceutically acceptable salts thereof, to pharmaceutical compositions comprising such compounds and salts, and to methods of using such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer.Type: GrantFiled: October 10, 2018Date of Patent: February 25, 2020Assignee: Pfizer Inc.Inventors: Michael Raymond Collins, Robert Steven Kania, Robert Arnold Kumpf, Pei-Pei Kung, Daniel Tyler Richter, Scott Channing Sutton, Martin James Wythes
-
Publication number: 20190270737Abstract: The present invention relates to compounds of formula (I) or pharmaceutically acceptable salts thereof, wherein A, L, D, R1-R15, w, x, y, and z are defined herein. The novel cycloalkyl-linked diheterocycle derivatives that are useful in the treatment of abnormal cell growth, such as cancer, in mammals. The present invention also relates to pharmaceutical compositions containing the compounds and to methods of using the compounds and compositions in the treatment of abnormal cell growth in mammals.Type: ApplicationFiled: May 20, 2019Publication date: September 5, 2019Applicant: Pfizer Inc.Inventors: Aaron Craig Burns, Michael Raymond Collins, Samantha Elizabeth Greasley, Robert Louis Hoffman, Peter Qinhua Huang, Robert Steven Kania, Pei-Pei Kung, Maria Angelica Linton, Lakshmi Sourirajan Narasimhan, Paul Francis Richardson, Daniel Tyler Richter, Graham Smith
-
Publication number: 20190040055Abstract: The present invention relates to compounds of formula (I) or pharmaceutically acceptable salts thereof, wherein A, L, D, R1-R15, w, x, y, and z are defined herein. The novel cycloalkyl-linked diheterocycle derivatives that are useful in the treatment of abnormal cell growth, such as cancer, in mammals. The present invention also relates to pharmaceutical compositions containing the compounds and to methods of using the compounds and compositions in the treatment of abnormal cell growth in mammals.Type: ApplicationFiled: October 11, 2018Publication date: February 7, 2019Applicant: Pfizer Inc.Inventors: Aaron Craig Burns, Michael Raymond Collins, Samantha Elizabeth Greasley, Robert Louis Hoffman, Peter Qinhua Huang, Robert Steven Kania, Pei-Pei Kung, Maria Angelica Linton, Lakshmi Sourirajan Narasimhan, Paul Francis Richardson, Daniel Tyler Richter, Graham Smith
-
Publication number: 20190040047Abstract: This invention relates to compounds of general formula (I) in which R1, R2, R3, R4, L, X and Z are as defined herein, and the pharmaceutically acceptable salts thereof, to pharmaceutical compositions comprising such compounds and salts, and to methods of using such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer.Type: ApplicationFiled: October 10, 2018Publication date: February 7, 2019Applicant: Pfizer Inc.Inventors: Michael Raymond Collins, Robert Steven Kania, Robert Arnold Kumpf, Pei-Pei Kung, Daniel Tyler Richter, Scott Channing Sutton, Martin James Wythes
-
Patent number: 10125130Abstract: The present invention relates to compounds of formula (I) or pharmaceutically acceptable salts thereof, wherein A, L, D, R1-R15, w, x, y, and z are defined herein. The novel cycloalkyl-linked diheterocycle derivatives that are useful in the treatment of abnormal cell growth, such as cancer, in mammals. The present invention also relates to pharmaceutical compositions containing the compounds and to methods of using the compounds and compositions in the treatment of abnormal cell growth in mammals.Type: GrantFiled: November 29, 2017Date of Patent: November 13, 2018Assignee: Pfizer Inc.Inventors: Aaron Craig Burns, Michael Raymond Collins, Samantha Elizabeth Greasley, Robert Louis Hoffman, Peter Qinhua Huang, Robert Steven Kania, Pei-Pei Kung, Maria Angelica Linton, Lakshmi Sourirajan Narasimhan, Paul Francis Richardson, Daniel Tyler Richter, Graham Smith
-
Publication number: 20180148441Abstract: The present invention relates to compounds of formula (I) or pharmaceutically acceptable salts thereof, wherein A, L, D, R1-R15, w, x, y, and z are defined herein. The novel cycloalkyl-linked diheterocycle derivatives that are useful in the treatment of abnormal cell growth, such as cancer, in mammals. The present invention also relates to pharmaceutical compositions containing the compounds and to methods of using the compounds and compositions in the treatment of abnormal cell growth in mammals.Type: ApplicationFiled: November 29, 2017Publication date: May 31, 2018Applicant: PFIZER INC.Inventors: Aaron Craig BURNS, Michael Raymond COLLINS, Samantha Elizabeth GREASLEY, Robert Louis Hoffman, Peter Qinhua HUANG, Robert Steven Kania, Pei-Pei KUNG, Maria Angelica LINTON, Lakshmi Sourirajan NARASIMHAN, Paul Francis RICHARDSON, Daniel Tyler RICHTER, Graham SMITH
-
Publication number: 20170298048Abstract: This invention relates to compounds of general formula (I) in which R1, R2, R3, R4, L, X and Z are as defined herein, and the pharmaceutically acceptable salts thereof, to pharmaceutical compositions comprising such compounds and salts, and to methods of using such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer.Type: ApplicationFiled: June 28, 2017Publication date: October 19, 2017Applicant: Pfizer Inc.Inventors: Michael Raymond Collins, Robert Steven Kania, Robert Arnold Kumpf, Pei-Pei Kung, Daniel Tyler Richter, Scott Channing Sutton, Martin James Wythes
-
Patent number: 9593097Abstract: Compounds of the general formula (I): processes for the preparation of these compounds, compositions containing these compounds, and the uses of these compounds.Type: GrantFiled: December 14, 2015Date of Patent: March 14, 2017Assignee: Pfizer Inc.Inventors: Ted William Johnson, Paul Francis Richardson, Michael Raymond Collins, Daniel Tyler Richter, Benjamin Joseph Burke, Sacha Ninkovic, Ketan Satish Gajiwala, Maria Angelica Linton, Phuong Thi Quy Le, Jacqui Elizabeth Hoffman
-
Publication number: 20170050958Abstract: The present invention relates to compounds of formula (I) or pharmaceutically acceptable salts thereof, wherein A, L, D, R1-R15, w, x, y, and z are defined herein. The novel cycloalkyl-linked diheterocycle derivatives that are useful in the treatment of abnormal cell growth, such as cancer, in mammals. The present invention also relates to pharmaceutical compositions containing the compounds and to methods of using the compounds and compositions in the treatment of abnormal cell growth in mammals.Type: ApplicationFiled: April 17, 2015Publication date: February 23, 2017Applicant: PFIZER INC.Inventors: Aaron Craig BURNS, Michael Raymond COLLINS, Samantha Elizabeth GREASLEY, Robert Louis Hoffman, Peter Qinhua HUANG, Robert Steven Kania, Pei-Pei KUNG, Maria Angelica LINTON, Lakshmi Sourirajan NARASIMHAN, Paul Francis RICHARDSON, Daniel Tyler RICHTER, Graham SMITH
-
Publication number: 20160376254Abstract: This invention relates to compounds of general formula (I) in which R1, R2, R3, R4, L, X and Z are as defined herein, and the pharmaceutically acceptable salts thereof, to pharmaceutical compositions comprising such compounds and salts, and to methods of using such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer.Type: ApplicationFiled: September 12, 2016Publication date: December 29, 2016Applicant: Pfizer Inc.Inventors: Michael Raymond COLLINS, Robert Steven Kania, Robert Arnold Kumpf, Pei-Pei Kung, Daniel Tyler Richter, Scott Channing Sutton, Martin James Wythes
-
Publication number: 20160176850Abstract: Compounds of the general formula (I): processes for the preparation of these compounds, compositions containing these compounds, and the uses of these compounds.Type: ApplicationFiled: December 14, 2015Publication date: June 23, 2016Inventors: Ted William Johnson, Paul Francis Richardson, Michael Raymond Collins, Daniel Tyler Richter, Benjamin Joseph Burke, Sacha Ninkovic, Ketan Satish Gajiwala, Maria Angelica Linton, Phuong Thi Quy Le, Jacqui Elizabeth Hoffman
-
Publication number: 20150361067Abstract: This invention relates to compounds of general formula (I) in which R1, R2, R3, R4, L, X and Z are as defined herein, and the pharmaceutically acceptable salts thereof, to pharmaceutical compositions comprising such compounds and salts, and to methods of using such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer.Type: ApplicationFiled: June 16, 2015Publication date: December 17, 2015Applicant: PFIZER INC.Inventors: Michael Raymond Collins, Robert Steven Kania, Robert Arnold Kumpf, Pei-Pei Kung, Daniel Tyler Richter, Scott Channing Sutton, Martin James Wythes
-
Patent number: 8518952Abstract: The present invention is directed to compounds of formula (I), and pharmaceutically acceptable salts thereof, their synthesis, and their use as CHK-1 inhibitors.Type: GrantFiled: August 4, 2009Date of Patent: August 27, 2013Assignee: Pfizer Inc.Inventors: John Frederick Braganza, Michael Raymond Collins, John Charles Kath, Sacha Ninkovic, Hui Li, Daniel Tyler Richter
-
Publication number: 20110144084Abstract: The present invention is directed to compounds of formula (I), and pharmaceutically acceptable salts thereof, their synthesis, and their use as CHK-1 inhibitors.Type: ApplicationFiled: August 4, 2009Publication date: June 16, 2011Applicant: PFIZER INCInventors: John Frederick Braganza, Michael Raymond Collins, John Charles Kath, Sacha Ninkovic, Hui Li, Daniel Tyler Richter
-
Patent number: 7122670Abstract: The present invention relates to a method of making a compound of the formula wherein X1, X2 and R3—R4 are as defined herein. The method includes reacting a compound of the formula with an amine of formula 3 (HNR3R4) in the presence of a Lewis Acid and a non-nucleophilic base. The 2,4-diamino pyrimidine moiety is a common component in a variety of biologically active drug-like molecules and pyrimidine derivatives have been found to be useful in the treatment of abnormal cell growth, such as cancer, in mammals.Type: GrantFiled: August 27, 2004Date of Patent: October 17, 2006Assignee: Pfizer IncInventors: John Charles Kath, Daniel Tyler Richter, Michael Joseph Luzzio
